Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Shares Sold by Geode Capital Management LLC

Geode Capital Management LLC reduced its stake in shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) by 6.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 529,053 shares of the biopharmaceutical company’s stock after selling 39,464 shares during the quarter. Geode Capital Management LLC owned about 0.96% of Marinus Pharmaceuticals worth $283,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the company. Virtu Financial LLC bought a new position in Marinus Pharmaceuticals during the 4th quarter valued at $36,000. World Investment Advisors LLC purchased a new stake in shares of Marinus Pharmaceuticals in the third quarter worth approximately $104,000. Deltec Asset Management LLC acquired a new stake in shares of Marinus Pharmaceuticals during the 4th quarter valued at $107,000. JPMorgan Chase & Co. grew its stake in Marinus Pharmaceuticals by 1,968.5% in the third quarter. JPMorgan Chase & Co. now owns 133,191 shares of the biopharmaceutical company’s stock valued at $234,000 after purchasing an additional 126,752 shares in the last quarter. Finally, Franklin Resources Inc. increased its holdings in Marinus Pharmaceuticals by 34.9% in the third quarter. Franklin Resources Inc. now owns 4,713,014 shares of the biopharmaceutical company’s stock worth $8,483,000 after buying an additional 1,219,871 shares during the last quarter. Institutional investors and hedge funds own 98.80% of the company’s stock.

Marinus Pharmaceuticals Stock Down 0.2 %

MRNS stock opened at $0.55 on Friday. Marinus Pharmaceuticals, Inc. has a twelve month low of $0.22 and a twelve month high of $1.97. The business has a 50 day moving average price of $0.55 and a two-hundred day moving average price of $0.51. The company has a market cap of $30.32 million, a price-to-earnings ratio of -0.22 and a beta of 1.03.

Wall Street Analysts Forecast Growth

Separately, StockNews.com assumed coverage on Marinus Pharmaceuticals in a report on Sunday, April 27th. They issued a “sell” rating for the company. One analyst has rated the stock with a sell rating, seven have given a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $4.79.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.